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Abstract
Objective To assess the incidence, cofactors, and excess risk of
development of non-alcoholic fatty liver disease, including
non-alcoholic steatohepatitis, attributable to tamoxifen in
women.
Design Prospective, randomised, double blind, placebo
controlled trial.
Setting and participants 5408 healthy women who had had
hysterectomies, recruited into the Italian tamoxifen
chemoprevention trial from 58 centres in Italy.
Intervention Women were randomly assigned to receive
tamoxifen (20 mg daily) or placebo for five years.
Main outcome measure Development of non-alcoholic fatty
liver disease in all women with normal baseline liver function
who showed at least two elevations of alanine aminotransferase
( ≥ 1.5 times upper limit of normal) over a six month period.
Results During follow up, 64 women met the predefined
criteria: 12 tested positive for hepatitis C virus, and the
remaining 52 were suspected of having developed
non-alcoholic fatty liver disease (34 tamoxifen, 18
placebo)—hazard ratio = 2.0 (95% confidence interval 1.1 to 3.5;
P = 0.04). In all 52 women ultrasonography confirmed the
presence of fatty liver. Other factors associated with the
development of non-alcoholic fatty liver disease included
overweight (2.4, 1.2 to 4.8), obesity (3.6, 1.7 to 7.6),
hypercholesterolaemia (3.4, 1.4 to 7.8), and arterial
hypertension (2.0, 1.0 to 3.8). Twenty women had liver biopsies:
15 were diagnosed as having mild to moderate steatohepatitis
(12 tamoxifen, 3 placebo), and five had fatty liver alone (1
tamoxifen, 4 placebo). No clinical, biochemical, ultrasonic, or
histological signs suggestive of progression to cirrhosis were
observed after a median follow up of 8.7 years.
Conclusions Tamoxifen was associated with higher risk of
development of non-alcoholic steatohepatitis only in
overweight and obese women with features of metabolic
syndrome, but the disease, in both the tamoxifen and the
placebo group, after 10 years of follow up seems to be indolent.
Introduction
Tamoxifen is a well known antioestrogen used for the hormone
treatment of oestrogen receptor positive breast cancer, and its
efficacy in preventing breast cancer in women at high risk has
been recently recognised. It is associated with an increased risk of
endometrial cancer and other adverse reactions,1 including the
development of non-alcoholic fatty liver and non-alcoholic
steatohepatitis.2–4 We aimed to evaluate the incidence of,
potential risk factors for, and excess risk attributable to
tamoxifen in non-alcoholic fatty liver diseases in a large cohort
of women who had had hysterectomies and were originally
enrolled in the Italian tamoxifen chemoprevention randomised
trial.
Methods
The Italian tamoxifen chemoprevention trial included healthy
women aged 35 to 70 who had had a total hysterectomy in order
to avoid the associated risk of endometrial cancer.5 6 The study
started in October 1992, and recruitment ended in 1997.
Women were randomly assigned in a double blind manner to
receive tamoxifen (20 mg daily) or placebo for five years.Women
with severe concurrent illness were excluded from randomisa-
tion. At baseline, women had a thorough physical examination
and blood testing, and a complete history was taken. Follow up
included a physical examination every six months and blood
testing and mammography every 12 months.6
Design of the study on incidence of non-alcoholic fatty liver
disease
In 1992, in the absence of information about liver toxicity of
tamoxifen, we included a surveillance programme in the Italian
trial with the aim of identifying and assessing the onset of acute
or chronic liver injury.6 We suspected development of
non-alcoholic fatty liver disease in all women with normal base-
line transaminase concentrations and no history of liver enzyme
alterations who developed chronic unexplained hypertransami-
nasaemia defined as multiple elevations of alanine aminotrans-
ferase ≥ 1.5 times the normal upper limit over a six month
period. We chose this arbitrary criterion to justify the morbidity
and to limit the number of false positive liver biopsies in women
at normal risk.7 For each woman identified, we collected detailed
information on previous liver function tests, hepatitis B or C
infection, autoantibodies indicative of autoimmune hepatitis,
iron metabolism, alcohol intake, and use of hepatotoxic drugs, in
order to exclude recognised causes of liver disease. Women with
unexplained hypertransaminasaemia had a ultrasound examina-
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tion of the liver and were offered liver biopsy for final diagnosis.
Both procedures were done by operators blind to the treatment
allocation. We invited all women with suspected non-alcoholic
fatty liver disease to a repeat physical examination, blood tests,
and ultrasonography in March 2004, and those who had had
biopsies were invited to a repeat procedure.
Statistical analysis
We used Fisher’s exact test to assess statistical differences in the
frequency of the outcomes among women in the different study
groups.We used the Kaplan-Meier method to assess the cumula-
tive incidence of events reported during follow up and the
log-rank test to compare the frequency of events between
groups. We assessed the independent effect of multiple factors
on the development of events during the trial by using Cox pro-
portional hazards regression. We based all analyses on assigned
treatment (intention to treat).
Results
From 1992 to 1997, 5408 women (median age 51 years) who
were well and had had hysterectomies were randomised to
receive tamoxifen (n = 2708) or placebo (n = 2700) for five
years.5 Three hundred and twenty one (5.9%) women had
alanine aminotransferase above the normal upper limit at base-
line but were considered eligible to enter the trial. Of these, 223
maintained alanine aminotransferase < 1.5 times the normal
upper limit during intervention, 52 had a concentration ≥ 1.5
times the normal upper limit at a single visit, and 46 had such a
concentration on two or more occasions. Of the 5087 women
with normal alanine aminotransferase at baseline, 4853
maintained normal concentrations during intervention, 170 had
a single concentration ≥ 1.5 times the normal upper limit during
intervention, and 64 had two or more results ≥ 1.5 times the
normal upper limit over at least six months (table 1). Of these 64
women, 12 tested positive for hepatitis C virus. The remaining 52
women, who fulfilled our criteria, were invited to have a liver
biopsy for final diagnosis. In all cases ultrasonic findings were
consistent with the presence of fatty liver.
Women with high alanine aminotransferase at baseline were
heavier, had a higher body mass index, and more often had dia-
betes than women with normal concentrations at baseline and
during follow up (P < 0.0001). A similar proportion of women in
these two groups had moderate to severe hypercholesterolaemia
or hypertension normalised by treatment. Among women with
normal alanine aminotransferase at baseline, development of
suspected non-alcoholic fatty liver disease was associated with
baseline hypercholesterolaemia ( > 6.5 mmol/l) (P = 0.005) and
hypertension (P = 0.15) (table 2).
The mean weight of the 52 women with suspected
non-alcoholic fatty liver disease was 71.5 kg at randomisation
and 74.4 kg at the first elevation of alanine aminotransferase
(P < 0.0001). During the intervention, five women (two placebo,
three tamoxifen) developed acute hepatitis (aminotransferase
≥ 10 times normal upper limit); four tested positive for hepatitis
C, and for one (on placebo) the cause remained unknown.
Liver biopsies
Twenty women (13 tamoxifen, 7 placebo) had liver biopsy: 15
had steatohepatitis (12 tamoxifen, 3 placebo), and 5 had fatty
liver (1 tamoxifen, 4 placebo). The positive predictive value for
non-alcoholic steatohepatitis was 92% in the tamoxifen group
and 43% in the placebo group. The mean weight of the 15
women with steatohepatitis was 70.2 kg at randomisation and
73.5 kg at the time of first elevation of alanine aminotransferase
(P = 0.015), whereas the mean weight of the five women with
fatty liver remained stable (69.2 kg at randomisation, 69.8 kg at
first alanine aminotransferase elevation; P = 0.68). The women
who refused biopsy did not differ in any of the considered char-
acteristics from those who agreed to have the procedure (table
2). Six of the 15 women diagnosed as having non-alcoholic stea-
tohepatitis had a mild liver biopsy score according to Brunt,8 and
nine had a moderate score; 10 had grade 1 fibrosis, and five had
grade 2 fibrosis, but no severe fibrosis occurred.
Three additional women with elevated alanine aminotrans-
ferase at baseline had liver biopsy on the advice of their family
doctor or local hepatologist. All received tamoxifen and fulfilled
our criteria for suspected non-alcoholic fatty liver disease. The
first woman was obese, had diabetes, and was diagnosed as hav-
ing liver cirrhosis. However, her low platelet count (105 000/
mm3), prolonged prothrombin time, and aspartate:alanine
aminotransferase ratio > 1 before enrolment suggested the
presence of pre-existing cirrhosis. Of the two remaining women,
one had moderate liver fibrosis and the other had severe fibrosis.
Cumulative incidence of suspected non-alcoholic fatty liver
disease
Suspicion of non-alcoholic fatty liver disease was more common
in the tamoxifen group (n = 34) than in the placebo group
(n = 18) (log rank P = 0.017) (figure). This excess was, however,
limited to the first two years of intervention (tamoxifen 21,
placebo 7), and no excess was apparent thereafter (tamoxifen 13,
Table 1 Distribution of women in Italian tamoxifen chemoprevention trial according to alanine aminotransferase concentrations and hepatitis B or C virus
profile
Results Total (n=5408) Placebo (n=2708) Tamoxifen (n=2700) P value*
High ALT at baseline (>ULN): 321 (5.9%) 161 (5.9%) 160 (5.9%)
Normal ALT during follow up 223 114 109 Reference
Single elevation of ALT during follow up (≥1.5×ULN) 52 29 23 0.644
Multiple elevations of ALT during follow up
(≥1.5×ULN)
46 18 28 0.148
Normal ALT at baseline: 5087 2547 2540
Normal ALT during follow up 4853 2433 2420 Reference
Single elevation of ALT during follow up (≥1.5×ULN) 170 92 78 0.312
Multiple elevations of ALT during follow up
(≥1.5×ULN)
64 22 42 0.016
Positive for hepatitis B/C virus or antinuclear
antibody
12 4 8 0.265
Possible non-alcoholic fatty liver disease 52 18 34 0.036
ALT=alanine aminotransferase; ULN=upper limit of normal.
*Fisher’s exact test.
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placebo 11). The mean interval between randomisation and first
elevation of alanine aminotransferase was 23 (range 6-50)
months, similar in both study groups.
Compared with the placebo group, the cumulative incidence
of suspected non-alcoholic fatty liver disease after five years in the
tamoxifen group was particularly high (3.8%, 95% confidence
interval 1.6% to 6.0%) among obese women (body mass index
> 30), moderately high (2.4%, 1.2% to 3.5%) among overweight
women (body mass index 25-30), but similar (0.7%, 0.2% to 1.2%)
in women of normal weight (body mass index < 25) (figure).
The incidence of suspected non-alcoholic fatty liver disease
in women with normal alanine aminotransferase at baseline
reached 0.37/100 women/year in the tamoxifen group
compared with 0.19/100 in the placebo group. On the basis of
the liver biopsy findings, we can reasonably assume that all
women in the tamoxifen group and half of the women in the
placebo group had steatohepatitis. Therefore, the rate of steato-
hepatitis would be approximately 0.4/100 women/year in the
tamoxifen group compared with 0.1/100 in the placebo group,
with an excess rate of steatohepatitis attributed to tamoxifen of
0.3/100 women/year. Similarly, among obese women the rate of
steatohepatitis during the first two years of intervention would be
1.13/100 women/year in the tamoxifen group compared with
0.07/100 in the placebo group (table 3).
Prognostic factors for tamoxifen associated suspected
non-alcoholic fatty liver disease
Overall, tamoxifen was associated with an increased risk of
developing suspected non-alcoholic fatty liver disease (hazard
ratio = 2.0, 95% confidence interval 1.1 to 3.5), but the
association was restricted to overweight women (2.3, 1.2 to 4.6).
Other predictors of non-alcoholic fatty liver disease included
overweight (2.4, 1.2 to 4.8), obesity (3.6, 1.7 to 7.6), severe baseline
hypercholesterolaemia ( > 7.8 mmol/l) (3.4, 1.4 to 7.8), and
hypertension (2.0, 1.0 to 3.8) (table 4).
Among overweight and obese women, tamoxifen and hyper-
tension were independent significant predictors for the develop-
ment of suspected non-alcoholic fatty liver disease. Among
women in the placebo group, diabetes (10.6, 2.9 to 38.6) and
severe hypercholesterolaemia ( > 7.8 mmol/l) (8.4, 2.5 to 28.3)
were associated with an excess risk of developing suspected non-
alcoholic fatty liver disease. Among women in the tamoxifen
Table 2 Baseline characteristics of women in Italian tamoxifen chemoprevention trial
Characteristic
High ALT at
baseline
Normal ALT at baseline
Normal ALT during follow up
Single elevation of ALT
(≥1.5×ULN)
Multiple elevations of ALT (≥1.5×ULN)
HBV/HCV/ANA(+)
NAFLD
Suspected* Confirmed†
All participants 321 4853 170 12 52 20
Tamoxifen group 160 2420 78 8 34 13
Placebo group 161 2433 92 4 18 7
Median age (years):
All participants 51 51 51 54 51 50
Tamoxifen 52 51 50 54 51 50
Placebo 50 52 51 54 51 49
Median weight (kg):
All participants 70 64 69 63 70 70
Tamoxifen 70 65 67 60 70 69
Placebo 67 64 70 73 71 72
Median body mass index (kg/m2):
All participants 27.0 25.0 27.1 26.0 28.1 27.3
Tamoxifen 27.6 25.0 26.6 26.0 28.2 28.0
Placebo 26.3 25.0 27.7 25.3 26.7 25.9
Diabetes (No (%)):
All participants 17 (5.3) 89 (1.8) 6 (3.5) – 3 (5.8) 1 (5.0)
Tamoxifen 11 (6.9) 48 (2.0) 2 (2.6) – 0 0
Placebo 6 (3.7) 41 (1.7) 4 (4.3) – 3 (16.7) 1 (14.3)
Median cholesterol (mmol/l):
All participants 5.8 5.9 5.8 6.2 6.2 6.5
Tamoxifen 5.7 5.9 5.7 6.2 6.0 6.4
Placebo 5.9 5.9 5.8 6.1 6.6 6.6
Cholesterol 6.5-7.8 mmol/l (No (%)):
All participants 75 (23.4) 1202 (24.8) 23 (13.5) 4 (33.3) 14 (26.9) 7 (35.0)
Tamoxifen 35 (21.9) 607 (25.1) 11 (14.1) 3 (37.5) 8 (23.5) 5 (38.5)
Placebo 40 (24.8) 599 (24.6) 12 (13.0) 1 (25.0) 6 (33.3) 2 (28.6)
Cholesterol >7.8 mmol/l (No (%)):
All participants 13 (4.0) 244 (5.0) 11 (6.5) – 7 (13.5) 3 (15.0)
Tamoxifen 6 (3.8) 120 (5.0) 4 (5.1) – 3 (8.8) 1 (7.7)
Placebo 7 (4.3) 124 (5.1) 7 (7.6) – 4 (22.2) 2 (28.6)
Hypertension‡ (No (%)):
All participants 49 (15.3) 623 (12.8) 27 (15.9) 2 (16.7) 13 (25.0) 5 (25.0)
Tamoxifen 31 (19.4) 300 (12.4) 12 (15.4) 1 (12.5) 8 (23.5) 4 (30.7)
Placebo 18 (11.2) 323 (13.3) 15 (16.3) 1 (25.0) 5 (27.8) 1 (14.3)
ALT= alanine aminotransferase; HBV/HCV/ANA(+)=positive for hepatitis B/C virus or antinuclear antibody; NAFLD=non-alcoholic fatty liver disease; ULN=upper limit of normal.
*Women with normal ALT at baseline, with two or more elevations of ALT ≥1.5×ULN during follow up over at least six months and with no evidence of hepatitis B or C virus infection.
†Diagnosis of NAFLD confirmed by biopsy.
‡Normalised by treatment.
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group, only overweight (3.2, 1.3 to 7.9) and obesity (5.4, 2.1 to
14.1) were associated with an excess risk of developing suspected
non-alcoholic fatty liver disease (table 4).
Follow up
Women with suspected non-alcoholic fatty liver disease were
blindly invited to suspend treatment.During follow up (median 6.9
years, range 2.7-9.9), 22 women had persistently normalised liver
enzymes, 14 had fluctuations of transaminases, and 16 maintained
high liver enzymes; we found no difference between the tamoxifen
and placebo groups. For the 20 women who had biopsies, the
mean time between observation of the first elevation of alanine
aminotransferase and last visit was 8.7 (range 4.9-10.7) years. In
this group, 11 women had features of the metabolic syndrome
(arterial hypertension, obesity, diabetes, dyslipidaemia), two had an
abnormal oral glucose tolerance test, and 14 had a homoeostasis
model assessment test result that suggested insulin resistance; no
difference existed between study groups or histological diagnosis
of fatty liver or steatohepatitis. No drug treatment for insulin
resistance was initiated. During follow up, three of the women who
had persistently abnormal alanine aminotransferase had a second
liver biopsy after 5-6.5 years. These repeated biopsies showed no
histological changes. In March 2004, according to our pre-
established clinical, biochemical, and ultrasonic criteria, none of
the 52 women had signs of cirrhosis.
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Cumulative incidence of suspected non-alcoholic fatty liver disease in women with normal alanine aminotransferase at baseline who participated in the Italian tamoxifen
chemoprevention trial, according to baseline body mass index
Table 3 Patient-years of observation and incidence of suspected non-alcoholic fatty liver disease (women with high alanine aminotransferase at baseline
excluded) in Italian tamoxifen chemoprevention trial, according to body mass index and treatment group
Body mass index (kg/m2) Total
<25 25-30 >30
Tamoxifen group
Events/woman-year 7/4670 16/3197 11/1341 34/9208
Rate/100 women/year (%) 0.15 0.50 0.82 0.37
First and second years:
Events/woman-year 5/2156 9/1506 7/619 21/4281
Rate/100 women/year (%) 0.23 0.60 1.13 0.49
Third to fifth years:
Events/woman-year 2/2514 7/1691 4/722 13/4927
Rate/100 women/year (%) 0.08 0.41 0.55 0.26
Placebo group
Events/woman-year 6/4885 7/3329 5/1405 18/9619
Rate/100 women/year (%) 0.12 0.21 0.36 0.19
First and second years:
Events/woman-year 4/2238 2/1537 1/665 7/4440
Rate/100 women/year (%) 0.18 0.13 0.15 0.16
Third to fifth years:
Events/woman-year 2/2647 5/1792 4/740 11/5179
Rate/100 women/year (%) 0.08 0.28 0.54 0.21
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Discussion
This study showed that treatment with 20 mg of tamoxifen daily
for up to five years was associated with an excess risk of develop-
ing non-alcoholic steatohepatitis in overweight and obese, but
otherwise healthy, women who had had hysterectomies.
Criteria for the identification of non-alcoholic fatty liver
disease
Our arbitrary cut-off point of 1.5 times the normal upper limit
for alanine aminotransferase with multiple elevations over a six
month period could be criticised, as chronic liver disease in both
viral infection and fatty liver can occur with lower and intermit-
tent elevations of liver enzymes and also in the absence of abnor-
mal alanine aminotransferase.9 10 As the main objective of our
study was to recognise more severe disease and not fatty liver in
itself, and in the absence of defined standard, we adopted these
criteria to ethically justify offering liver biopsy. Interestingly, the
same cut-off point was used in a recent study on the prevalence
and severity of non-alcoholic fatty liver diseases, assessed on his-
tological basis, in a large series of Italian patients.11 Furthermore,
both Matteoni et al and Ratziu et al reported that
aminotransferase concentrations seem to be higher in patients
with more severe histological lesions (steatonecrosis and fibrosis)
than in those with steatosis alone,12 13 and the prevalence of stea-
tohepatitis and fibrosis at histological examination is low even in
high risk patients identified with stringent criteria.14
We found a single point elevation of alanine aminotrans-
ferase in 170 women. Although we cannot exclude the possibil-
ity that some of the women who had a single alteration of alanine
aminotransferase may have developed non-alcoholic fatty liver
disease, we found no difference in the two study arms, indicating
no additional risk attributable to tamoxifen.
Cofactors associated with the development of tamoxifen
related steatohepatitis
Although tamoxifen might induce hepatic fat content,15 the
mechanism by which it can lead to fibrosis has not yet been iden-
tified. Obesity, which has been associated with hepatic steatosis, is
an emerging risk factor for progression of fibrosis in many chronic
liver diseases.16 In our study, body mass index was strongly associ-
ated with the development of suspected non-alcoholic fatty liver
disease. We can speculate that, despite normal liver enzymes at
enrolment, obese women had an underlying fatty liver.17 In this
context, our results support the “multiple hit” hypothesis, suggest-
ing that fatty liver is vulnerable to oxidants, with progression to
steatohepatitis occurring when a second agent (such as tamoxifen)
generates liver cell death, inflammation, and activation of stellate
cells with production of fibrosis.
In contrast with previous case reports,3 4 the women in our
trial developed only mild to moderate steatohepatitis, and we
found no cirrhosis. This discrepancy can be explained, as we
excluded women with a history of abnormal liver enzymes or
elevated baseline alanine aminotransferase, which could be
attributed to undiagnosed non-alcoholic fatty liver disease.18 In
these women, the incidence of persistently high alanine
aminotransferase was significantly greater than in the group with
normal liver enzymes at baseline and was slightly higher in the
tamoxifen group. Moreover, as steatohepatitis with advanced
fibrosis and cirrhosis was confirmed by biopsy in three women
on tamoxifen with altered alanine aminotransferase at baseline,
we suggest that such women might be at risk of developing more
severe disease when receiving tamoxifen.
Natural history of non-alcoholic fatty liver disease
The association of fatty liver with inflammatory changes and
fibrosis in women who do not drink alcohol was largely ignored
as a clinical disorder until Ludwig et al coined the term
non-alcoholic steatohepatitis.19 Actually, its prevalence in
westernised countries is estimated at 15-20% and can be as high
as 90% in high risk subgroups.20 In this clinical study we have
estimated for the first time the incidence of development of per-
sistent mild elevations of alanine aminotransferase suggestive of
non-alcoholic fatty liver disease in a cohort of low risk women
receiving placebo. All women had had hysterectomies, satisfied
the inclusion criteria, and agreed to participate in a
chemoprevention trial, but they were not selected for concurrent
illness or for any feature of the metabolic syndrome, which is
known to be associated with the risk of developing non-alcoholic
fatty liver disease. Our results therefore could be representative
of the general Italian female population.
Several retrospective studies have suggested an association
between non-alcoholic steatohepatitis and severe liver disease,
including hepatocellular carcinoma.21 In our study, none of the
15 women with histologically confirmed steatohepatitis has
developed clinical, biochemical, or ultrasonic features suggestive
of cirrhosis after a median follow up of 8.7 years, and none of the
three women who had a repeated biopsy showed histological
changes. This suggests that liver fibrosis, when recognised early,
remains stable over the years and that progression to cirrhosis is
rare, in agreement with other studies.22–24
Conclusion
This prospective study indicates that 20 mg of tamoxifen daily is
associated with a higher risk of developing non-alcoholic steato-
hepatitis in healthy women who had had hysterectomies. The
risk is low (hazard ratio = 2.0, 95% confidence interval 1.1 to 3.5),
restricted to women with body mass index ≥ 25, associated with
obesity and features of the metabolic syndrome, and limited to
the first two years of treatment. During this period, the identifica-
tion of unexplained abnormal alanine aminotransferase ( ≥ 1.5
Table 4 Prognostic factors for development of suspected non-alcoholic fatty liver disease in women with normal baseline transaminase concentrations in
Italian tamoxifen chemoprevention trial. Values are hazard ratios (95% confidence intervals) obtained from Cox regression model
Multivariate analysis All women
Body mass index (kg/m2) Treatment arm
<25 ≥25 Placebo Tamoxifen
Tamoxifen 2.0 (1.1 to 3.5) 1.2 (0.4 to 3.7) 2.3 (1.2 to 4.6) – –
Age 1.0 (0.9 to 1.0) 1.0 (0.9 to 1.0) 1.0 (0.9 to 1.0) 1.0 (0.9 to 1.0) 1.0 (0.9 to 1.0)
Body mass index 25-30 2.4 (1.2 to 4.8) – – 1.4 (0.4 to 4.2) 3.2 (1.3 to 7.9)
Body mass index >30 3.6 (1.7 to 7.6) – – 2.0 (0.6 to 7.0) 5.4 (2.1 to 14.1)
Diabetes 1.9 (0.6 to 6.2) – 2.3 (0.7 to 7.6) 10.6 (2.9 to 38.6) –
Cholesterol 6.5-7.8 mmol/l 1.3 (0.7 to 2.5) 1.4 (0.3 to 5.6) 1.3 (0.6 to 2.7) 2.4 (0.8 to 7.0) 0.9 (0.4 to 2.1)
Cholesterol >7.8 mmol/l 3.4 (1.4 to 7.8) 7.7 (1.9 to 31.8) 2.3 (0.8 to 6.8) 8.4 (2.5 to 28.3) 2.2 (0.6 to 7.4)
Hypertension* 2.0 (1.0 to 3.8) 2.0 (0.4 to 9.2) 2.1 (1.0 to 4.3) 2.0 (0.7 to 6.1) 2.0 (0.9 to 4.5)
*Normalised by treatment.
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times the normal upper limit) in women receiving tamoxifen is
associated with development of non-alcoholic fatty liver disease
and accurately predicts the presence of fibrosis at histology,
reducing the need for liver biopsy. In the placebo group, the
annual incidence of persistent mild elevation of alanine
aminotransferase associated with ultrasonic and histological fea-
tures of non-alcoholic fatty liver disease was 0.19/100
women/year. Mild to moderate non-alcoholic steatohepatitis,
when recognised at the onset, seems to be indolent in the long
term. Our results also apply to women with breast cancer who
are eligible to receive tamoxifen treatment.
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Amendment
This is version 2 of the paper. In this version, the incorrect
statement that the participating women had had breast cancer
has been removed from the abstract and from the
introduction, results, and discussion section.
What is already known on this topic
Non-alcoholic fatty liver disease is very common, although
the annual incidence is unknown; major risk factors are
obesity, hyperlipidaemia, and diabetes
Tamoxifen has been occasionally associated with the
development of non-alcoholic steatohepatitis, characterised
by necro-inflammation and fibrosis in addition to fatty liver
What this study adds
In women on placebo, the incidence of persistently abnormal
alanine aminotransferase suggestive of non-alcoholic fatty
liver disease is low (0.19/100 women/year)
Tamoxifen is associated with a twofold increased risk of
developing non-alcoholic steatohepatitis, but only in
overweight women
During tamoxifen treatment, unexplained multiple
elevations of alanine aminotransferase ≥ 1.5 times the
upper normal limit are associated with steatohepatitis,
making histological examination unnecessary
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